Clinical Trial: Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia

Brief Summary:

BL22 is a type of protein that scientists have created to interact with certain cancer cells. Experiments have shown that BL22 can bind with cancer cells that have a particular kind of protein (called CD22 ) on their surface, and can kill those cells. CD22 is present on certain types of hairy cell leukemia (HCL) cancer cells, and researchers have been working on treatments that will use BL22 and other related proteins to interact with and kill these kinds of cancer cells. The primary purpose of this study will be to provide access to and treatment with BL22 for patients who have HCL in order to determine their response to the treatment. In addition, the study will assess potential side effects of BL22 and examine why some patients respond better than others to treatment with BL22 and related therapies.

This study will include about 21 to 25 adults who have been diagnosed with forms of HCL that have not responded well to standard treatments such as surgery, chemotherapy, or radiation therapy. These adults also will have received anti-CD22 therapies before, potentially including treatments with BL22, and have not developed immunity or resistance to these treatments.

Prior to the study, patients will undergo a 1- to 2-week screening period to assess their eligibility for treatment. Eligible patients will participate in the study for up to 16 cycles of treatment, with each cycle lasting approximately 4 weeks. For each cycle, patients will receive 1 prescribed dose of BL22 every other day for a total of 3 doses per cycle, and will be assessed after every cycle to evaluate the success of the treatment. During the evaluation visits, patients will be required to have a brief physical examination, give blood and urine samples for testing, and undergo other tests as need to check heart and kidney function and assess the state of the

Detailed Summary:

Background:

BL22, also called CAT-3888 or RFB4(dsFv)-PE38, is a recombinant immunotoxin containing an Fv fragment of an anti-CD22 monoclonal antibody and truncated Pseudomonas exotoxin (PE).

In Phase 1 and 2 trials in patients with chemoresistant hairy cell leukemia (HCL), BL22 showed 47-61% complete remission (CR) rates and 12% of HCL patients had a completely reversible hemolytic uremic syndrome (HUS).

A mutant of BL22, termed CAT-8015 or HA22, differs by 3 amino acids and has higher binding affinity to CD22 compared to BL22 (15-fold greater). CAT-8015 is currently undergoing Phase 1 testing in HCL and other diseases.

HCL patients who have previously received recombinant anti-CD22 immunotoxin (BL22, CAT-8015, or LMB-2) may benefit from additional BL22 administration.

Objectives:

The primary objective is to provide access to BL22 for HCL patients who have previously received BL22, CAT-8015, or LMB-2, or are ineligible for CAT-8015, but may benefit from BL22. The primary outcome will be response to treatment.

Secondary objectives:

  • Determine immunogenicity and safety profiles of BL22 in patients with prior immunotoxin, using aspirin/enoxaparin to prevent HUS.
  • To correlate response to ex vivo sensitivity of HCL cells, obtained from blood with or without apheresis, to BL22 and to other recombinant anti-CD22 immunotoxins such as CAT-8015, and to tumor markers.
  • To correlate neutralizing antibodies with number of cycles of BL22, type
    Sponsor: National Cancer Institute (NCI)

    Current Primary Outcome: Number of Months to Response to Treatment [ Time Frame: 2/14/2009 till 6/24/2010 ]

    Response is defined by the Response Evaluation Criteria in the protocol, namely the earliest point where all relevant tests (i.e. lab tests, physical exam, radiology results) are consistent with complete response (CR) or partial response (PR). CR or PR must be confirmed for at least 4 weeks. Complete response: No evidence of leukemic cells by routine H/E stains of the peripheral blood and bone marrow. Partial response:neutrophils >/= 1,500/micrograms/L or 50% improvement over baseline without growth factors for at least 4 weeks.


    Original Primary Outcome: Provide BL22 to patients who have relapsed after immunotoxin treatment ans determine response rate in this population.

    Current Secondary Outcome:

    • Number of Participants With Adverse Events [ Time Frame: 2 years & 6 months ]
      Here are the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.
    • Number of Participants With Complete Response (CR) Who Resolve the Bone Marrow Abnormality by Magnetic Resonance Imaging (MRI) [ Time Frame: Bone marrow biopsy and MRI 4 weeks after patients meeting blood criteria for CR, and if CR is present, repeat bone marrow biopsy and MRI every 12 months. Bone marrow biopsy and MRI is not done in patients with PR as best response. ]
      Patients are assessed by MRI to determine which ones resolve their marrow abnormality. A non-parametric Wilcoxon test was to be used to determine whether CR correlated with resolution of MRI abnormality
    • Number of Patients Who Developed Neutralizing Antibodies After One or More Cycles of BL22 [ Time Frame: 24 weeks ]
      Fresh malignant cells are isolated from blood, bone marrow, lymph nodes or other tissue and incubated with recombinant immunotoxins to determine sensitivity to BL22 and other agents to estimate the amount of cancer cells in the body by measuring proteins which fall off cancer cells and go into the blood.
    • Number of Patients With ex Vivo Sensitivity Who Respond Clinically [ Time Frame: Time to CR can be between 2 months and 1 year ]
      Although some hairy cell leukemia (HCL) cells from some patients may have ex vivo sensitivity, they might not respond clinically. Number of participants with pretreatment ex vivo sensitivity (<10 ng/ml IC50) who go on to achieve CR as best response. CR required abscence of HCL in the bone marrow and resolution of cytopenias.
    • Percentage of Patients Who Respond Clinically, Who Also Have Normalization in sCD22 or sCD25 [ Time Frame: patients may undergo lymphapheresis before the first and/or later cycles up to 12 months after achieving CR or PR ]
      CD25 (sCD25)and CD22 (sCD22) quantify hairy cell leukemia (HCL) tumor burden. Patients with either PR or CR are evaluated for soluble forms of CD25 (sCD25) and soluble CD22 (sCD22). The number of patients with PR or CR who have normalization of sCD25 and sCD22 will be recorded. Normalization is considered <3 ng/ml for sCD25, and <2 ng/ml for sCD22. Patients will be assessed for normalization of sCD25 and sCD22 for at least 12 months after achieving PR or CR.
    • Correlation Between Number of Prior Cycles of BL22 With Immunogenicity on This Protocol [ Time Frame: Within 2 months of end of treatment ( measure antibodies before each cycle) ]
      Percent of patients neutralizing >75% of 1000 ng/ml of BL22 in a biologic assay by end of treatment, with respect to the number of prior cycles of BL22 prior to entry on this protocol
    • Percentage of Patients Who Make Antibodies [ Time Frame: 24 weeks ]
      Determination of antibodies against BL22 is determined by the Clinical Laboratory Improvement Amendments (CLIA) certified blood tests in our contract lab. NCI-Frederick in the laboratory of Dr. David Waters (Science Applications International Corporation (SAIC). He is CLIA certified.
    • Percentage of Patients Who Have Dose Limiting Toxicity (DLT) [ Time Frame: 24 weeks ]
      Determination of dose limiting toxicity (DLT) is by the standard toxicity assessment Common Terminology Criteria for Adverse Events version 3.0 (CTCAEv3.0) done every cycle. For detailed information about the CTCAEv3.0 see the protocol Link module.


    Original Secondary Outcome: Obtain additional safety information on BL22 and correlate response to tumor burden, tumor markers, neutralizing antibodies, and PK values.

    Information By: National Institutes of Health Clinical Center (CC)

    Dates:
    Date Received: June 17, 2009
    Date Started: February 2009
    Date Completion:
    Last Updated: October 7, 2015
    Last Verified: October 2015